# Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma

> **NCT05371093** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Kite, A Gilead Company** · enrollment: 231 (actual)

## Conditions studied

- Relapsed/Refractory Follicular Lymphoma

## Interventions

- **BIOLOGICAL:** Axicabtagene Ciloleucel
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Lenalidomide
- **DRUG:** Rituximab
- **DRUG:** Doxorubicin
- **DRUG:** Vincristine
- **DRUG:** Prednisone
- **DRUG:** Bendamustine

## Key facts

- **NCT ID:** NCT05371093
- **Lead sponsor:** Kite, A Gilead Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-09-22
- **Primary completion:** 2030-10
- **Final completion:** 2030-10
- **Target enrollment:** 231 (ACTUAL)
- **Last updated:** 2025-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05371093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05371093, "Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT05371093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*